|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 15, 2017 ) Alzheimer’s disease (AD) is the most common cause of progressive dementia in the geriatric population. There has been a sudden and sharp rise in the prevalence of Alzheimer’s disease cases across the world, emphasizing the need of an efficient treatment to cure the disease.
Currently, very less therapeutic alternatives are available in the market and none of them provides a total remedy for this condition. Therefore, new players’ entry into this market will offer attractive growth perspective to the industry players.The Global market is projected to reach USD 12.43 billion by 2022, at a CAGR of 4.62% from 2017 to 2022.
Alzheimer’s Disease Therapeutics and Diagnostics Market: Drivers & Restraints
The growth of the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is majorly attributed to factors like increasing old age population, growing R&D investment, high prevalence of Alzheimer’s and neurodegenerative disorders, and better life expectancy of the population. Bur, factors like high cost of treatment and no proper reimbursement scenario are hampering the growth of this market.
Get accurate market forecast and analysis on the Alzheimer’s Disease Therapeutics and Diagnostics Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/global-alzheimers-disease-therapeutics-and-diagnostics-market-2247/request-sample
Alzheimer’s Disease Therapeutics and Diagnostics Market: Segmentation
By Therapeutics
• Marketed Drugs
o NMDA Receptor Antagonists
o Cholinesterase Inhibitors
• Pipeline Drugs
By Diagnostics
• Computed tomography scan
• Electroencephalography
• Lumbar puncture test
• Magnetic resonance imaging
• Positron emission tomography
• Others
By Geography
• North America
o United States
o Canada
• Europe
o U.K
o Spain
o Germany
o Italy
o France
• Asia-Pacific
o China
o India
o Japan
o Australia
o South Korea
• Latin America
o Brazil
o Argentina
o Mexico
o Rest of Latin America
• Middle East & Africa
o Middle-East
o Africa
Alzheimer’s Disease Therapeutics and Diagnostics Market: Overview
As of 2017, the global Alzheimer’s disease Therapeutics and Diagnostics market was worth USD 9.92 billion and is expected to show a decent growth in the forecasting period. Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. Based on Diagnostics, Computed tomography scan segment dominates the market. Lack of alternative imaging devices for brain and neurological diagnostics is one of the major causes for its big share.
North America is estimated to be the biggest market for Alzheimer’s disease Therapeutics and Diagnostics owing to the increasing prevalence of Alzheimer’s disease and extensive technological advancement in the region. With the growth in geriatric populace in the developing regions of Asia Pacific, this market is predicted to show the highest CAGR in the forecast period.
Alzheimer’s Disease Therapeutics and Diagnostics Market: Key Players
The Alzheimer’s Disease Therapeutics and Diagnostics market is highly competitive with a large number of players. Some of the major Companies are AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, Abbvie Inc., Pfizer Inc., Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
